Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of metronomic capecitabine as a treatment for hepatocellular carcinoma (HCC). Eight studies were included, involving a total of 476 patients. The analysis found that metronomic capecitabine showed a pooled prevalence of disease control rate (DCR) of 36% and an objective response rate (ORR) of 7%. The median progression-free survival (PFS) was 3.57 months and the median overall survival (OS) was 11.75 months. The incidence of grade 3-4 adverse events (AEs) was 38%. The study suggests that metronomic capecitabine could be a potential second-line therapy for HCC, but effective management of its side effects is crucial. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)